Here we discuss the clinical therapeutic development of HDAC6 inhibitors against B cell-associated hematological malignancies, including those resistant to targeted therapies, and summarized HDAC6 inhibitors used in preclinical or clinical investigations (Table 1). This evidence concerns the gene HDAC6 and hematologic disorder.